Shopping Cart
- Remove All
- Your shopping cart is currently empty
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | 41 € | In Stock | |
25 mg | 89 € | In Stock | |
50 mg | 152 € | In Stock | |
100 mg | Inquiry | In Stock | |
1 mL x 10 mM (in DMSO) | 28 € | In Stock |
Description | Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease. |
In vivo | Valiglurax (0.3-30 mg/kg; po) reversed haloperidol-induced catalepsy (HIC) in rats[1]. |
Alias | VU-2957, VU2957, VU-0652957, VU0652957, VU 2957, VU 0652957 |
Molecular Weight | 329.28 |
Formula | C16H10F3N5 |
Cas No. | 1976050-09-5 |
Smiles | C(F)(F)(F)C=1C2=C(C=C(NC=3C=4C(NN3)=NC=CC4)C=C2)C=CN1 |
Relative Density. | 1.530 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 112.5 mg/mL (341.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.